BioPharmSignal logoBioPharmSignal

Biotech News

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

NEXGEL (NXGL)NEXGEL2026-06-25 13:46 ESTCompany update

NXGL (NXGL) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is nxgl.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction

NXGLNEXGEL2026-06-25 13:46 EST

NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors

View all latest news

NEXGEL

NEXGEL is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

NXGLNEXGEL2026-06-26 10:42 EST

NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th

NXGLNEXGEL2026-06-26 10:42 EST

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

NXGLNEXGEL2026-06-26 10:42 EST

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

NXGLNEXGEL2026-06-26 10:42 EST

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NXGLNEXGEL2026-06-26 10:42 EST

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States